Alnylam's Onpattro: Not Following FDA Guidance Amplifies Clinical Meaningfulness Concerns

 
• By Sarah Karlin-Smith
  
image of the heart (organ)
FDA advisors will vote on a supplemental indication for Onpattro for the treatment of ATTR cardiomyopathy 13 September. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from United States

More from North America